These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19409058)

  • 21. Coinfection with HIV and HCV: more questions than answers?
    Waldrep TW; Summers KK; Chiliade PA
    Pharmacotherapy; 2000 Dec; 20(12):1499-507. PubMed ID: 11130222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction.
    Schaefer M; Sarkar R; Diez-Quevedo C
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S111-7. PubMed ID: 23884058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
    Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
    Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression.
    Hauser P
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S35-50. PubMed ID: 15081102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms.
    Maddock C; Baita A; Orrù MG; Sitzia R; Costa A; Muntoni E; Farci MG; Carpiniello B; Pariante CM
    J Psychopharmacol; 2004 Mar; 18(1):41-6. PubMed ID: 15107183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
    Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.
    Loftis JM; Matthews AM; Hauser P
    Drugs; 2006; 66(2):155-74. PubMed ID: 16451091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C.
    Galvão-de Almeida A; Quarantini LC; Sampaio AS; Lyra AC; Parise CL; Paraná R; de Oliveira IR; Koenen KC; Miranda-Scippa A; Guindalini C
    Brain Behav Immun; 2011 Oct; 25(7):1491-7. PubMed ID: 21693183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
    Sterling RK; Sulkowski MS
    Semin Liver Dis; 2004; 24 Suppl 2():61-8. PubMed ID: 15346248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.
    Dieperink E; Willenbring M; Ho SB
    Am J Psychiatry; 2000 Jun; 157(6):867-76. PubMed ID: 10831463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [HIV-HCV co-infection: where are we now?].
    Piroth L
    Gastroenterol Clin Biol; 2009 Mar; 33 Suppl 2():S94-6. PubMed ID: 19375042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project.
    Lindenburg CE; Lambers FA; Urbanus AT; Schinkel J; Jansen PL; Krol A; Casteelen G; van Santen G; van den Berg CH; Coutinho RA; Prins M; Weegink CJ
    Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):23-31. PubMed ID: 21042221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C.
    Crone CC; Gabriel GM; Wise TN
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S27-32. PubMed ID: 15468615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients.
    Prestileo T; Mazzola G; Di Lorenzo F; Colletti P; Vitale F; Ferraro D; Di Stefano R; Cammà C; Craxì A
    Int J Antimicrob Agents; 2000 Nov; 16(3):373-8. PubMed ID: 11091068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
    Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
    AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case of mania induced by withdrawal of interferon-alpha in a patient affected by bipolar disorder.
    Rossi A; Renzetti D; D'Albenzio L; Gianfelice D; Kalyvoka A; Rinaldi O
    Psychiatry Clin Neurosci; 2002 Dec; 56(6):647-8. PubMed ID: 12485309
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
    Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Ma Q; Lu HZ
    Haemophilia; 2010 May; 16(3):502-7. PubMed ID: 20028427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.
    Huckans MS; Loftis JM; Blackwell AD; Linke A; Hauser P
    Subst Abuse Treat Prev Policy; 2007 Jan; 2():4. PubMed ID: 17222348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.
    Miller TR; Weiss JJ; Bräu N; Dieterich DT; Stivala A; Rivera-Mindt M
    J Neurovirol; 2017 Apr; 23(2):260-272. PubMed ID: 27896573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.